Evidence map›Paper›PMID 38463515›Full record

ReviewOpen medicine (Warsaw, Poland)2024

XRCC1 and hOGG1 polymorphisms and endometrial carcinoma: A meta-analysis.

Shengke He, Xiujuan Zhao, Ruifang Mu, Zhongjun Pan, Jinglan Mai

RetractedAbstract readReviewRetracted Publication
In one paragraph

Review in Open medicine (Warsaw, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Shengke HeDepartment of Pathology, Danzhou People's Hospital, Nada Town, Danzhou, Hainan, 571799, China.
Xiujuan ZhaoDepartment of Gynaecology and Obstetrics, Danzhou People's Hospital, Nada Town, Danzhou, Hainan, 571799, China.
Ruifang MuDepartment of Gynaecology and Obstetrics, Danzhou People's Hospital, Nada Town, Danzhou, Hainan, 571799, China.
Zhongjun PanDepartment of Pathology, Danzhou People's Hospital, Nada Town, Danzhou, Hainan, 571799, China.
Jinglan MaiOccupational Physical Examination Outpatient, Haikou Center for Disease Control and Prevention, No. 56 Yehai Avenue, Qiongshan District, Haikou, Hainan, 570203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma's (EC) etiology is complex and involves DNA repair gene polymorphisms like XRCC1-Arg399Gln and hOGG1-Ser326Cys, but their association with the disease is unclear. Following PRISMA, we conducted a systematic review and meta-analysis, collecting data from four databases. The studies needed to be population-based case-control studies examining the association between the named polymorphisms and EC. Quality was assessed with the Newcastle-Ottawa Scale. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated, and subgroup analyses were conducted based on ethnicity. Seven studies were included. Both polymorphisms were found to significantly increase EC risk, particularly in Caucasians. XRCC1-Arg399Gln showed a dominant model OR of 1.14 (95% CI: 1.01-1.29) and a homozygous model OR of 1.59 (95% CI: 1.12-2.25). The heterozygote model OR for hOGG1-Ser326Cys was 1.29 (95% CI: 1.02-1.63), and the allele OR was 1.31 (95% CI: 1.07-1.60). XRCC1-Arg399Gln and hOGG1-Ser326Cys may increase EC risk, primarily in Caucasian women, emphasizing the role of DNA repair in disease susceptibility. More extensive studies are needed to validate these findings in diverse ethnicities and investigate other DNA repair gene polymorphisms.

Indexed as

endometrial carcinomagenetic susceptibilityhOGG1-Ser326Cysmeta-analysispolymorphismXRCC1-Arg399Gln

Identifiers

PMID38463515
PMCPMC10921453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.